Abstract P3-06-05: Human endogenous retrovirus-K (HERV-K) is aberrantly expressed in triple negative breast cancer (TNBC) and associated with increased distant metastasis: Impact of HERV-K knockdown on gene expression patterns and invasive potential of mesenchymal TNBC

Autor: Sharon A Glynn, Dibyangana Bhattacharyya, Shauna Lambe, Emma Kerr, Simon McDade, Faizan H Khan, Eoin Dervan, Feng Wang-Johanning, Sean Hynes, Grace Callagy

Publikováno v: Cancer Research. 82:P3-06

Background: Human endogenous retrovirus K (HERV-K) belongs to a family of endogenous retroviruses that are present in our genome with similarities to present day exogenous retroviruses. HERV-K, like other endogenous retroviruses, is transmitted verti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2047c58feca104db59a8730934c2837a
https://doi.org/10.1158/1538-7445.sabcs21-p3-06-05

Supplementary Data 1 from Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer

Autor: Sandra Van Schaeybroeck, Sarah Ross, Melissa J. LaBonte, Chris Winnington, Jose Sousa, Jochen H.M. Prehn, Andreas U. Lindner, Manisha Maurya, Shauna Lambe, Christopher J. Scott, Simon S. McDade, Frederica Di Nicolantonio, Alberto Bardelli, Lyndsey Hanson, Daryl Griffin, Mustasin Rassel, Cheryl H. Latimer, Rebecca Briggs, Hajrah Khawaja

antibodies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ba82bc4493ab5ff598581035f75294
https://doi.org/10.1158/1535-7163.22523061.v1

Data from Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer

Autor: Sandra Van Schaeybroeck, Sarah Ross, Melissa J. LaBonte, Chris Winnington, Jose Sousa, Jochen H.M. Prehn, Andreas U. Lindner, Manisha Maurya, Shauna Lambe, Christopher J. Scott, Simon S. McDade, Frederica Di Nicolantonio, Alberto Bardelli, Lyndsey Hanson, Daryl Griffin, Mustasin Rassel, Cheryl H. Latimer, Rebecca Briggs, Hajrah Khawaja

Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant (MT) colorectal cancer. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed. Small-molec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2546072b012549475335793c8492b489
https://doi.org/10.1158/1535-7163.c.6543573.v1

Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer

Autor: Hajrah Khawaja, Rebecca Briggs, Cheryl H. Latimer, Mustasin Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Frederica Di Nicolantonio, Simon S. McDade, Christopher J. Scott, Shauna Lambe, Manisha Maurya, Andreas U. Lindner, Jochen H.M. Prehn, Jose Sousa, Chris Winnington, Melissa J. LaBonte, Sarah Ross, Sandra Van Schaeybroeck

Publikováno v: Khawaja, H, Briggs, R, Latimer, C H, Rassel, M, Griffin, D, Hanson, L, Bardelli, A, Di Nicolantonio, F, McDade, S S, Scott, C J, Lambe, S, Maurya, M, Lindner, A U, Prehn, J H M, Sousa, J, Winnington, C, LaBonte, M J, Ross, S & Van Schaeybroeck, S 2023, ' Bcl-xL is a key mediator of apoptosis following KRAS G12C inhibition in KRAS G12C-mutant colorectal cancer ', Molecular Cancer Therapeutics, vol. 22, no. 1, pp. 135–149 . https://doi.org/10.1158/1535-7163.mct-22-0301

Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant (MT) colorectal cancer. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed. Small-molec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8b03203b5408aea5f0c7e4b9ff2129c
https://hdl.handle.net/2318/1888885

Bcl-xL and association with apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer

Autor: Hajrah Khawaja, Rebecca Briggs, Cheryl Latimer, Md A.M.B Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Federica Di Nicolantonio, Simon McDade, Christopher Scott, Shauna Lambe, Manisha Maurya, Andreas Ulrich Lindner, Jochen HM Prehn, Jose Sousa, Chris Winnington, Melissa J LaBonte, Sarah Ross, Sandra Van Schaeybroeck

Publikováno v: Journal of Clinical Oncology. 40:3557-3557

3557 Background: Novel covalent inhibitors of KRASG12C have shown modest response rates in KRASG12C mutant (MT) colorectal cancer (CRC) patients. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd65836cf76e388783591fb28c99b175
https://doi.org/10.1200/jco.2022.40.16_suppl.3557